国家药品抽检合格率稳定在99.4%以上 三大重点举措“护航”用药安全

Core Insights - The National Medical Products Administration (NMPA) has successfully completed the goals set in the "14th Five-Year Plan" with a drug inspection pass rate stabilizing at over 99.4% [1][5] - The NMPA has implemented three key measures to ensure the safety and effectiveness of medications for the public [1] Group 1: Regulatory Measures - The NMPA conducts over 200,000 drug inspections, 20,000 medical device inspections, and 20,000 cosmetic inspections annually, ensuring 100% coverage of selected products in national procurement [1][3] - The NMPA adheres to internationally recognized standards for the quality and efficacy evaluation of generic drugs [1] Group 2: Support for Pharmaceutical Development - The NMPA has established four expedited approval channels for breakthrough therapies, conditional approvals, priority reviews, and special approvals to support high-quality development in the pharmaceutical industry [3] - Since the beginning of the "14th Five-Year Plan," China has approved 204 innovative drugs and 265 innovative medical devices, with 50 innovative drugs and 49 innovative medical devices approved in the first seven months of this year [5] Group 3: Focus on Traditional Chinese Medicine and Special Populations - The NMPA is promoting the innovation and development of traditional Chinese medicine, having approved 27 innovative traditional Chinese medicines since the start of the "14th Five-Year Plan" [5] - A total of 387 pediatric drugs and 147 rare disease drugs have been approved since the beginning of the "14th Five-Year Plan," addressing the medication needs of key populations [9]